Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Shares Outstanding (Diluted Average) (2016 - 2020)

GT Biopharma (GTBP) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $4.4 million as the latest value for Q4 2020.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 29.59% to $4.4 million in Q4 2020 year-over-year; TTM through Dec 2020 was $4.4 million, a 29.59% increase, with the full-year FY2020 number at $4.4 million, up 29.59% from a year prior.
  • Shares Outstanding (Diluted Average) was $4.4 million for Q4 2020 at GT Biopharma, down from $70.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $70.1 million in Q1 2020 to a low of -$22.42 in Q2 2017.
  • A 5-year average of $19.8 million and a median of $5.6 million in 2017 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 100.0% in 2017, then surged 26023.93% in 2018.
  • GT Biopharma's Shares Outstanding (Diluted Average) stood at $81460.0 in 2016, then tumbled by 79.41% to $16769.0 in 2017, then soared by 298845.69% to $50.1 million in 2018, then crashed by 93.25% to $3.4 million in 2019, then increased by 29.59% to $4.4 million in 2020.
  • Per Business Quant, the three most recent readings for GTBP's Shares Outstanding (Diluted Average) are $4.4 million (Q4 2020), $70.1 million (Q1 2020), and $3.4 million (Q4 2019).